![conference banner](/images/conference-banner.jpeg)
Abstract
Apoptosis, the cells intrinsic death program, is a key regulator of tissue homeostasis. Thus, any imbalance between cell death and proliferation may favor tumor formation. Moreover, killing of cancer cells by cytotoxic therapies currently used in clinical oncology such as chemotherapy or γ-irradiation is primarily mediated by triggering apoptosis as well as other forms of cell death in cancer cells. Accordingly, defects in apoptosis pathways may lead to cancer resistance. Understanding the molecular pathways that regulate apoptosis in different types of malignancies and how resistant cancer cells successfully evade to undergo apoptosis may provide novel opportunities for cancer drug development. Thus, apoptosis pathways may be exploited for cancer treatment by directly triggering cell death in tumor cells, e.g. via ligation of death receptors, or by enhancing the efficacy of conventional cancer therapies, e.g. by blockade of anti-apoptotic programs. In this review we will focus on the potential exploitation of the death receptor pathway, in particular TRAIL, for cancer therapy. Also, we will discuss signal transduction therapy targeting Inhibitor of Apoptosis Proteins (IAPs).
Current Signal Transduction Therapy
Title: Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Volume: 1 Issue: 2
Author(s): Simone Fulda and Klaus-Michael Debatin
Affiliation:
Keywords: Apoptosis, cancer, TRAIL, IAP
Abstract: Apoptosis, the cells intrinsic death program, is a key regulator of tissue homeostasis. Thus, any imbalance between cell death and proliferation may favor tumor formation. Moreover, killing of cancer cells by cytotoxic therapies currently used in clinical oncology such as chemotherapy or γ-irradiation is primarily mediated by triggering apoptosis as well as other forms of cell death in cancer cells. Accordingly, defects in apoptosis pathways may lead to cancer resistance. Understanding the molecular pathways that regulate apoptosis in different types of malignancies and how resistant cancer cells successfully evade to undergo apoptosis may provide novel opportunities for cancer drug development. Thus, apoptosis pathways may be exploited for cancer treatment by directly triggering cell death in tumor cells, e.g. via ligation of death receptors, or by enhancing the efficacy of conventional cancer therapies, e.g. by blockade of anti-apoptotic programs. In this review we will focus on the potential exploitation of the death receptor pathway, in particular TRAIL, for cancer therapy. Also, we will discuss signal transduction therapy targeting Inhibitor of Apoptosis Proteins (IAPs).
Export Options
About this article
Cite this article as:
Fulda Simone and Debatin Klaus-Michael, Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers, Current Signal Transduction Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157436206777012075
DOI https://dx.doi.org/10.2174/157436206777012075 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Opportunities for Photoacoustic-Guided Drug Delivery
Current Drug Targets Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design Delivery and Application of Dietary Polyphenols to Target Organs, Tissues and Intracellular Organelles
Current Drug Metabolism Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Polyisoprenylation Potentiates the Inhibition of Polyisoprenylated Methylated Protein Methyl Esterase and the Cell Degenerative Effects of Sulfonyl Fluorides
Current Cancer Drug Targets Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry A Review of Current and Prospective Treatments for Channelopathies, with a Focus on Gene and Protein Therapy
Current Pharmaceutical Design Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Pharmacological Targeting of the Hsp70 Chaperone
Current Topics in Medicinal Chemistry Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design Effects of Plants and Isolates of Celastraceae Family on Cancer Pathways
Anti-Cancer Agents in Medicinal Chemistry Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Peptido-Targeting of the Mitochondrial Transition Pore Complex for Therapeutic Apoptosis Induction
Current Pharmaceutical Design Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Computer Modeling of Brain Tumor Growth
Mini-Reviews in Medicinal Chemistry Transition Metal-mediated Uncaging Chemistry in Prodrug Design
Current Topics in Medicinal Chemistry